Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Oral Oncology|June 19, 2018
Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trialMarco Siano, Vittoria Espeli, Nicolas Mach, et al.
Critical Reviews in Oncology/Hematology|March 20, 2021
Live European School of Oncology e-Sessions (e-ESO)Marco Siano, Francesca Marangoni, Nicholas Pavlidis, et al.
The Oncologist|June 9, 2017
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell CancerMarco Siano, Francesca Molinari, Vittoria Martin, et al.
Critical Reviews in Oncology/Hematology|May 17, 2019
The point of pain in head and neck cancerPaolo Bossi, Raffaele Giusti, Achille Tarsitano, et al.
Therapeutic Advances in Medical Oncology|January 13, 2025
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trialsCristina Gurizzan, Michela Cinquini, Lorenzo Legramandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac functionMarco Siano, Erika Lerch, Laura Negretti, et al.
Swiss Medical Weekly|May 20, 2019
Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort StudyEmanuel Lengwiler, Susanne Stampf, Alfred Zippelius, et al.
Oral Oncology|June 1, 2017
Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapyMarco Siano, Gabriele Infante, Carlo Resteghini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 15, 2018
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)Cedric M Panje, Konstantin J Dedes, Klazien Matter-Walstra, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 24, 2016
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?Stefan Diem, Fabienne Keller, Reinhard Rüesch, et al.
Pageof 4